The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
CLINICAL SYNTHESISFull Access

Psychiatric Pharmacogenomics

Published Online:https://doi.org/10.1176/foc.4.3.339

The field of psychiatric genomics has developed dramatically over the past 10 years. The essential goal of psychiatric pharmacogenomics is to measure genetic variation in individual patients to predict their response to psychotropic medications. The initial application of pharmacogenetic testing has been to identify patients who have structural and functional changes in their drug-metabolizing enzyme genes that are associated with increased serum levels of medication at standard doses. More recently, genetic variance in the serotonin transporter gene and the serotonin 2A receptor gene has been used to predict the response of patients to selective serotonin reuptake inhibitors.